When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer?

Research output: Contribution to journalArticleAcademicpeer-review

28 Citations (Scopus)


Until the publication of two pivotal trials, there were no treatment options available that did prolong the overall survival in men with hormone refractory prostate cancer (HRPC). Currently, docetaxel-based cytotoxic treatment is considered as a standard of care in all the patients with progressive metastatic HRPC. The use of this treatment regimen renders an equal survival benefit in all the subgroups of patients; however, there is a substantial difference in the overall survival between the subgroups. This review addresses the optimal timing of the cytotoxic treatment in asymptomatic patients with HRPC. (C) 2008 Elsevier Ltd. All rights reserved.
Original languageUndefined/Unknown
Pages (from-to)1193-1197
Number of pages5
JournalEuropean Journal of Cancer
Issue number9
Publication statusPublished - 2008

Cite this